Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open‐label study
Open Access
- 22 October 2024
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 99 (12) , 2313-2320
Abstract
Autoimmune hemolytic anemia (AIHA) is a group of acquired autoimmune disorders characterized by red blood cell hemolysis. In a phase 2, open‐label, multicenter study, adults with warm AIHA, cold agglutinin disease, or mixed‐type AIHA were administered once‐daily 1.0 or 2.5 mg parsaclisib (selective phosphoinositide 3‐kinase δ inhibitor) orally for 12 weeks, followed by an extension period. Dose increases (for AIHA worsening) or decreases (for tolerability) were permitted. Primary efficacy endpoint was the proportion of patients with complete (≥12 g/dL hemoglobin [Hgb]) or partial (10–12 g/dL Hgb or ≥2 g/dL increase from baseline) response at any visit during weeks 6–12 not attributable to transfusion. Among 25 enrolled patients (median age, 63 y), 16 (64%) achieved a partial or complete Hgb response during weeks 6–12. Responses were observed by week 1 in 52.0% of patients with incremental improvements during weeks 6–12 and sustained responses during the extension period. Responses were higher among patients with warm AIHA versus other types (75.0% vs. 44.4%). Clinically meaningful improvements in Functional Assessment of Chronic Illness Therapy‐Fatigue scores were observed at weeks 6 and 12. All patients had treatment‐emergent adverse events (TEAEs), most commonly diarrhea (32.0%) and pyrexia (28.0%). Grade ≥3 TEAEs occurred in 13 patients (52.0%). TEAEs considered possibly related to treatment occurred in 11 patients (44.0%). No dose reductions were required; six patients (24%) discontinued for a TEAE. In summary, parsaclisib was well tolerated and resulted in substantial improvements in Hgb response at week 1, with durable responses through the extension period.Clinical trial registration: This trial was registered at ClinicalTrials.gov (NCT03538041).Keywords
Funding Information
- Incyte
This publication has 32 references indexed in Scilit:
- Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double‐blind, placebo‐controlled, global study (FORWARD)American Journal of Hematology, 2023
- Interleukin 6 exacerbates the progression of warm autoimmune hemolytic anemia by influencing the activity and function of B cellsScientific Reports, 2023
- Practical therapy for primary autoimmune hemolytic anemia in adultsClinical and Experimental Medicine, 2022
- Autoimmune Hemolytic AnemiasNew England Journal of Medicine, 2021
- Epidemiology of autoimmune hemolytic anemia: A nationwide population‐based study in FranceAmerican Journal of Hematology, 2021
- Sutimlimab in Cold Agglutinin DiseaseNew England Journal of Medicine, 2021
- Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus MeetingBlood Reviews, 2020
- Warm Autoimmune Hemolytic AnemiaNew England Journal of Medicine, 2019
- Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centersAmerican Journal of Hematology, 2018
- Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studiesVaccine, 2010